Skip to content
Screener

Total Equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$22.32B+28.0%
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$1.53B+8.8%
Cytokinetics logo
CytokineticsCYTK
-$173.49M+52.9%
PTC Therapeutics logo
PTC TherapeuticsPTCT
-$180.47M+2.9%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$865.06M+29.3%
Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
$374.08M+44.8%

Other financials

Income statement

See full
Operating income-$54.1M-17.7%
Net income-$49.0M-20.1%
EPS (diluted)-$0.46-7.0%

Balance sheet

See full
Cash & equivalents$33.2M-33.5%
Total debt$3.8M-16.8%
Total assets$518.5M+14.1%

Cash flow

See full
Operating cash flow-$42.5M-12.4%
CapEx$260.0K+491%
Free cash flow-$42.8M-12.9%

Valuation

See full
Market cap$4.78B+236%
Enterprise value$4.75B+244%

Returns & leverage

See full
Return on equity-38.1%+13.4pp
Debt / equity0.0×
Current ratio22.6×+1.6×

Where this comes from

Reported directly by Edgewise Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The source filing: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 8:09 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-056713
AssetsAs of / March 31, 2026 / (unaudited)As of / December 31, 2025
Stockholders' equity:
Preferred stock, $.0001 par value per share; 200,000,000 shares authorized and no shares issued or outstanding as of March 31, 2026 and December 31, 2025
Common stock, $.0001 par value per share; 1,000,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 107,481,522 shares and 106,249,579 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively1010
Additional paid-in capital1,088,8291,067,941
Accumulated other comprehensive income (loss)(252)677
Accumulated deficit(595,384)(546,371)
Total stockholders' equity493,203522,257
Total liabilities and stockholders' equity$518,522$552,603

Item 1. Financial Statements (Unaudited)

FAQ

What is Edgewise Therapeutics, Inc.'s total equity?
Edgewise Therapeutics, Inc. (EWTX) reported total equity of $493.2M in Q1 2026.
How has Edgewise Therapeutics, Inc.'s total equity changed year-over-year?
Edgewise Therapeutics, Inc.'s total equity increased by 14.8% year-over-year, from $429.72M to $493.2M.
What is the long-term trend for Edgewise Therapeutics, Inc.'s total equity?
Over 5 years (2020 to 2025), Edgewise Therapeutics, Inc.'s total equity has grown at a 73.3% compound annual growth rate (CAGR), from -$33.42M to $522.26M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Ask your AI about Edgewise Therapeutics, Inc.'s total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude